⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12571283 | 1.00 | — | — | |
| SCHEMBL10591916 | 1.00 | — | — | |
| SCHEMBL12940444 | 1.00 | — | — | |
| SCHEMBL23749632 | 1.00 | — | — | |
| SCHEMBL13979525 | 1.00 | — | — | |
| SCHEMBL23748424 | 1.00 | — | — | |
| SCHEMBL28041801 | 0.82 | SLC7A5 (0.38) | — | |
| SCHEMBL14064946 | 0.82 | SLC7A5 (0.38) | — | |
| SCHEMBL14151987 | 0.80 | SLC7A5 (0.36) | — | |
| SCHEMBL825007 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162960-B2 | Selectin inhibitors, composition, and uses related thereto | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2024168123-A1 | SYNTHESIS OF CORE 2 O-SIALYL LEWIS-X POLYSACCHARIDES | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024114953-A1 | PHYLLOCHLORIN ANALOGUES SUITABLE FOR USE IN PHOTODYNAMIC THERAPY (PDT) | RMW CHO GROUP LIMITED (CN) | 2024-06-06 | — | — | WO | disclosed |
| US-20240067702-A1 | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11814444-B2 | Cyclic polypeptides for PCSK9 inhibition | RA PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023173132-A1 | ANTI-GLP1R ANTIBODY-DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023153932-A1 | ANTIBIOTIC COMPOUNDS, FORMULATIONS AND METHODS OF USE | UNIVERSITEIT LEIDEN (NL) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023094679-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094677-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094680-A1 | PHOTODYNAMIC THERAPY AND DIAGNOSIS | RMW CHO GROUP LIMITED (CN) | 2023-06-01 | — | — | WO | disclosed |
| US-10961189-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2021013250-A1 | HETEROCYCLIC AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海济煜医药科技有限公司 | 2021-01-28 | — | — | WO | disclosed |
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. | 2021-01-21 | — | — | US | disclosed |
| WO-2018026763-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| WO-2013052362-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20120149710-A1 | SORTASE A INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-06-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |